Vicarious Surgical Reports $7.3 Million Net Loss, Shifts to OTCQB Market

Vicarious Surgical Inc. reported a net loss of $7.3 million for the three months ending March 31, 2026, a significant improvement compared to a net loss of $15.4 million during the same period in 2025. The company's loss from operations also decreased by 52% to $7.5 million, down from $15.7 million year-over-year. This reduction in losses was attributed to a 52% decrease in total operating expenses, which fell from $15.7 million to $7.5 million. The decline was primarily driven by reduced personnel-related expenses, which decreased by $5.7 million due to a 61% reduction in average headcount, as well as decreases in costs associated with inventory, supplies, and professional fees.

In terms of financial position, Vicarious Surgical's total assets decreased to $12.6 million as of March 31, 2026, down from $19.6 million at the end of 2025. Current assets also saw a decline, with cash and cash equivalents dropping to $1.4 million from $2.6 million, and short-term investments decreasing to $2.3 million from $7.2 million. The company reported an accumulated deficit of $253.4 million, reflecting ongoing challenges in achieving revenue generation, as it has yet to commercialize its surgical robotic system.

Strategically, Vicarious Surgical has undergone significant changes, including a shift in its stock market listing. Following a suspension from the NYSE due to not meeting market capitalization requirements, the company’s Class A common stock began trading on the OTCQB Venture Market on March 24, 2026. This transition to a less liquid market may impact the company's ability to raise capital and could affect stockholder value. The company is also pursuing a potential uplisting to the Nasdaq Capital Market, contingent on meeting specific requirements, which may include a reverse stock split.

Operationally, Vicarious Surgical is focused on developing its single-port surgical robot, the Vicarious Surgical System, which aims to enhance minimally invasive surgical procedures. The company estimates a market potential of 45 million soft tissue surgeries annually, with ventral hernia procedures being the initial target application. However, the company has not yet generated revenue and does not expect to do so until it receives FDA authorization for its product. The management has indicated that ongoing investments in research and development will continue to drive expenses, and they are actively seeking additional financing to support operations and product development.

Looking ahead, Vicarious Surgical faces substantial uncertainty regarding its ability to continue as a going concern. The company has indicated that its current cash and short-term investments may not be sufficient to support operations for the next twelve months. Management is exploring various financing options, including equity and debt financing, to address its capital needs. The company’s future performance will depend on its ability to secure funding, achieve regulatory approvals, and successfully commercialize its surgical system.